Barratt Gillian, Bretagne Stéphane
UMR CNRS 8612, Laboratoire de Physico-chimie, Pharmacotechnie et Biopharmacie, Univ. Paris-Sud II, Faculté de Pharmacie, IFR 141, Châtenay-Malabry, France.
Int J Nanomedicine. 2007;2(3):301-13.
The polyene antibiotic Amphotericin B (AMB) is one of the first therapeutic agents to be marketed commercially as nanosized formulations in which the drug is associated with lipids as liposomes or complexes. In this way, its renal toxicity is reduced and its therapeutic index improved. This review summarizes the particular properties of AMB which justify this type of formulation and the early work leading up to their development. The clinical results obtained in the treatment of fungal infections are reviewed and their activity against leishmaniasis is also evoked. Some newer formulations of AMB, based on both lipids and polymers are described. In particular, their potential by the oral and pulmonary routes are discussed. Finally, the development of targeted systems to deliver the drug to specific cells and tissues is considered.
多烯抗生素两性霉素B（AMB）是首批作为纳米制剂商业化销售的治疗药物之一，在这些制剂中，药物与脂质结合形成脂质体或复合物。通过这种方式，其肾毒性降低，治疗指数提高。本综述总结了AMB的特殊性质，这些性质证明了这种制剂类型的合理性以及其开发前期的早期工作。回顾了治疗真菌感染所获得的临床结果，并提及了其对利什曼病的活性。描述了一些基于脂质和聚合物的AMB新制剂。特别讨论了它们通过口服和肺部途径的潜力。最后，考虑了将药物递送至特定细胞和组织的靶向系统的开发。
